Literature DB >> 16459168

Identifying type Vicenza von Willebrand disease.

Alessandra Casonato1, Elena Pontara, Francesca Sartorello, Maria Grazia Cattini, Lisa Gallinaro, Antonella Bertomoro, Antonio Rosato, Roberto Padrini, Antonio Pagnan.   

Abstract

Increased clearance of von Willebrand factor (VWF) is one of the main features of type Vicenza von Willebrand disease (VWD), a variant with plasma and platelet VWF level discrepancies and unusually large VWF multimers. Diagnosing type Vicenza VWD may not be easy, due to its heterogeneous phenotype. Here we describe the criteria we adopted to identify type Vicenza in a large group of VWD patients. Emphasizing the contribution of platelet VWF by comparison with plasma values, a first step involved selecting the candidate Vicenza patients on the basis of low or very low plasma VWF and a normal platelet VWF content. After excluding type 2A and 2B VWD patients, who may have normal platelet VWF, 18 candidates were found to meet our selection criteria. Genetic analysis revealed that 15 patients (from 5 unrelated families) were type Vicenza VWD and that all carried both G2220A and G3614A type Vicenza mutations barring one, who only had the G3614A mutation. All patients had a reduced VWF survival, and all but the patient with the G3614A mutation alone had ultralarge VWF multimers. Thus, low-plasma VWF associated with a normal platelet VWF content may be a first useful indicator for identifying type Vicenza VWD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16459168     DOI: 10.1016/j.lab.2005.10.002

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

1.  The Bleeding Assessment Tool and laboratory data in the characterisation of a female with inherited haemophilia A.

Authors:  Viviana Daidone; Eva Galletta; Antonella Bertomoro; Alessandra Casonato
Journal:  Blood Transfus       Date:  2016-11-15       Impact factor: 3.443

2.  Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.

Authors:  Cynthia M Pruss; Mia Golder; Andrea Bryant; Carol A Hegadorn; Erin Burnett; Kimberly Laverty; Kate Sponagle; Aly Dhala; Colleen Notley; Sandra Haberichter; David Lillicrap
Journal:  Blood       Date:  2011-02-23       Impact factor: 22.113

3.  Von Willebrand disease type Vicenza: In search of a classification for the archetype of reduced von Willebrand factor survival.

Authors:  Alessandra Casonato; Eva Galletta; Federico Galvanin; Viviana Daidone
Journal:  EJHaem       Date:  2021-05-05

4.  Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.

Authors:  A Gézsi; U Budde; I Deák; E Nagy; A Mohl; A Schlammadinger; Z Boda; T Masszi; J E Sadler; I Bodó
Journal:  J Thromb Haemost       Date:  2010-01-17       Impact factor: 5.824

5.  Cryptic non-canonical splice site activation is part of the mechanism that abolishes multimer organization in the c.2269_2270del von Willebrand factor.

Authors:  Viviana Daidone; Eva Galletta; Luigi De Marco; Alessandra Casonato
Journal:  Haematologica       Date:  2019-07-18       Impact factor: 9.941

6.  Next-generation sequencing of von Willebrand factor and coagulation factor VIII genes: a cross-sectional study in Croatian adult patients diagnosed with von Willebrand disease.

Authors:  Ivana Lapić; Margareta Radić Antolic; Ana Boban; Desiree Coen Herak; Dunja Rogić; Renata Zadro
Journal:  Croat Med J       Date:  2022-04-30       Impact factor: 2.415

7.  The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial.

Authors:  Katarina D Kovacevic; Jürgen Grafeneder; Christian Schörgenhofer; Georg Gelbenegger; Gloria Gager; Christa Firbas; Peter Quehenberger; Petra Jilma-Stohlawetz; Andrea Bileck; Shuhao Zhu; James C Gilbert; Martin Beliveau; Bernd Jilma; Ulla Derhaschnig
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

8.  Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers.

Authors:  Annette E Bowyer; Karen J Goodfellow; Holger Seidel; Philipp Westhofen; Francesca Stufano; Anne Goodeve; Stephen Kitchen; Michael Makris
Journal:  Res Pract Thromb Haemost       Date:  2018-08-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.